Navigation Links
InVitria's Animal Free Lacromin(TM) Provides a Cost-Effective Improvement Over Transferrin
Date:10/23/2007

SACRAMENTO, Calif., Oct. 23 /PRNewswire/ -- InVitria has released data that shows that Lacromin, a recombinant growth factor for cell culture media outperforms transferrin and provides a cost-effective solution to rising transferrin costs. Because Lacromin is produced in a completely animal-free system, it provides improved productivity and safety over animal-derived alternatives including bovine and human transferrin. In addition data has shown that Lacromin significantly increased the productivity of antibody production when compared with these other sources of transferrin.

"We are excited about Lacromin and its success as safer, more productive replacement for transferrin," said Victor Hicks, Vice President and Commercial Director, InVitria. "Lacromin(TM) provides a cost-effective solution to the challenge of rising transferrin costs and increasing concern over the use of animal-derived ingredients in cell culture. Given the FDA's preference for non-animal derived cell culture media ingredients, animal-free recombinant proteins like Lacromin(TM) are a real breakthrough for this market."

InVitria markets Lacromin(TM) to customers that seek a serum-free and animal component free cell culture media source for their biopharmaceutical production.

About Lacromin(TM)

Lacromin(TM) is recombinant human lactoferrin derived from plants. Lacromin(TM) holds many advantages over current cell culture media ingredients:

-- Strong growth factor

Lacromin(TM) has been shown to promote cell growth in many cell lines,

including Chinese Hamster Ovary (CHO) cells and Mouse Hybridoma cells.

-- Outperforms Transferrin

Lacromin(TM) promotes higher cell density and reduces cell doubling

time when compared with Transferrin.

-- Replaces Animal Derived Transferrin

Since Lacromin(TM) is derived from plants, it is free of any viral or

prion contaminant risks.

-- Improves IgG Productivity

In Hybridoma cells, Lacromin(TM) increased IgG productivity by 50%

versus Transferrin and by 6% versus Fetal Bovine Serum (FBS).

About InVitria

InVitria is a global supplier of animal-free products for use in bioprocessing, excipients, research and diagnostics.

InVitria's mission is to develop and supply our customers with products that deliver faster time to market, enhanced productivity, and improved safety.

For more information about InVitria, see our website at http://www.InVitria.com

Or Contact:

info@InVitria.com

1-800-916-8311

Statements in this announcement other than historical data and information constitute forward looking statements that involve risks and uncertainties that could cause actual results to differ materially from those stated or implied by such forward-looking statements. Potential risks and uncertainties may include, but are not limited to, recent changes in senior management, fluctuations in operating results, market conditions and changes in technology and increased competition.


'/>"/>
SOURCE InVitria
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. A Positive Selection Assay for Mutation Analysis in Big Blue Animals
2. Transgenic Animals
3. Bifidobacterium animalis
4. Bifidobacterium animalis
5. The QIAGEN Guide to Animal Cell Culture
6. The QIAGEN Guide to Animal Cell Culture
7. The QIAGEN Guide to Animal Cell Culture
8. The QIAGEN Guide to Animal Cell Culture
9. The QIAGEN Guide to Animal Cell Culture
10. The QIAGEN Guide to Animal Cell Culture
11. An Animal-Free DNase I
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... ... May 20, 2016 , ... Korean researchers say Manumycin A triggers apoptosis, ... new way to treat the disease. Surviving Mesothelioma has just posted an article on ... several Korean institutions based their mesothelioma study on the fact the Manumycin A, a ...
(Date:5/19/2016)... 2016 There is no saying ... the relentless pressures in pricing and lack in consumer ... circle though - numerous opportunities are up for grabs ... ActiveWallSt.com,s presents four names in this sector: Portola Pharmaceuticals ... (NASDAQ: VTAE ), Anthera Pharmaceuticals Inc. (NASDAQ: ...
(Date:5/18/2016)... Calif. (PRWEB) , ... May 18, 2016 , ... ... awarded the Luis Villalobos Award to Cognition Therapeutics at the annual ACA Summit last ... company that is financed by one of ACA’s member angel groups. It is the ...
(Date:5/18/2016)... Washington, PA (PRWEB) , ... May 18, 2016 ... ... at least 1,200 hospitalizations are a direct result of asthma complications.* Costing more ... challenge across the country. , “For too many, the suffering ...
Breaking Biology Technology:
(Date:3/14/2016)... http://www.apimages.com ) - ... - Renvoi : image disponible via AP Images ( ... --> DERMALOG, le leader de l,innovation ... d,empreintes digitales pour l,enregistrement des réfugiés en Allemagne. ... produire des cartes d,identité aux réfugiés. DERMALOG dévoilera ...
(Date:3/10/2016)... March 10, 2016   Unisys Corporation (NYSE: ... Protection (CBP) is testing its biometric identity solution at ... to help identify certain non-U.S. citizens leaving the ... test, designed to help determine the efficiency and accuracy of ... February and will run until May 2016. --> ...
(Date:3/8/2016)... 2016   Valencell , the leading innovator ... has secured $11M in Series D financing. The ... venture fund being launched by UAE-based financial services ... investors TDF Ventures and WSJ Joshua Fund. Valencell ... triple-digit growth and accelerate its pioneering innovation in ...
Breaking Biology News(10 mins):